Dianthus Therapeutics, Inc. (DNTH)
- Previous Close
20.99 - Open
21.07 - Bid 21.28 x 100
- Ask 21.55 x 100
- Day's Range
20.69 - 21.80 - 52 Week Range
0.57 - 33.77 - Volume
75,496 - Avg. Volume
169,158 - Market Cap (intraday)
630.995M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-8.45 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.17
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
dianthustx.comRecent News: DNTH
Performance Overview: DNTH
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DNTH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DNTH
Valuation Measures
Market Cap
631.00M
Enterprise Value
457.86M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
39.21
Price/Book (mrq)
3.74
Enterprise Value/Revenue
162.02
Enterprise Value/EBITDA
-9.57
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.94%
Return on Equity (ttm)
-35.92%
Revenue (ttm)
2.83M
Net Income Avi to Common (ttm)
-43.55M
Diluted EPS (ttm)
-8.45
Balance Sheet and Cash Flow
Total Cash (mrq)
173.72M
Total Debt/Equity (mrq)
0.35%
Levered Free Cash Flow (ttm)
-22.81M